Obsessive-compulsive disorder. Obsessive-compulsive disorder
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Intervention group drug Riluzole 50 mg tablets once a day for 12 weeks. Intervention 2: Control group: Placebo group 1 tablet daily for 12 weeks
Sponsors
Deputy of research and technology developement
Eligibility
Sex/Gender
All
Age
No minimum to 65 Years
Inclusion criteria
Inclusion criteria: Patients with known obsessive compulsive disorder by DSM-V criteria. Not to use alcohol chronic. The patient had no serious risk factor for respiratory apnea and pulmonary fibrosis and not be affected. Between 18 to 65 years old The individual should be treated with a maximum dose of SSRI for at least 6 months and scored 20 or higher on the Y-BOCS criterion. The patient's liver transaminase should not be more than 5 times higher than normal.
Exclusion criteria
Exclusion criteria: Pregnancy and nursing; Patients with a history of memantine use. Patients who do not sign the ethical consent form or refuse to continue to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient's score in Y-BOCS test. Timepoint: Before intervention, 4, 8 and 12 weeks after intervention. Method of measurement: the list of Riluzole adverse effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad hosein Shiveh
Ahvaz University of Medical Sciences
Outcome results
None listed